DSM-5 introduced the anxious distress specifier in recognition of the significance of anxiety in patients who are depressed. Studies have supported the validity of the specifier in patients with major depressive disorder (MDD). In this report from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, we examined the validity of the specifier in patients with bipolar depression.
Methods
Forty-nine patients with a principal diagnosis of bipolar depression and 369 with MDD were evaluated with semi-structured diagnostic interviews, including the DSM-5 Anxious Distress Specifier Interview (DADSI). The patients were rated on measures of depression, anxiety, and irritability, and completed self-report measures.
Results
The majority of patients with bipolar depression met the DSM-5 anxious distress specifier, no different than the frequency in patients with MDD. The DADSI was significantly correlated with other measures of anxiety, and more highly correlated with other measures of anxiety than with measures of depression and irritability. Patients with panic and generalized anxiety disorder scored higher on the DADSI than patients without an anxiety disorder.
Conclusions
The results of our study indicate that anxious distress is common in patients with bipolar depression and support the validity of the DSM-5 anxious distress specifier.
Get full access to this article
View all access options for this article.
References
1.
FreemanMPFreemanSAMcElroySL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord.2002; 68: 1–23.
2.
PavlovaBPerlisRHMantereO. Prevalence of current anxiety disorders in people with bipolar disorder during euthymia: a meta-analysis. Psychol Med.2017; 47: 1107–1115.
3.
NabaviBMitchellAJNuttD.A lifetime prevalence of comorbidity between bipolar affective disorder and anxiety disorders: a meta-analysis of 52 interview-based studies of psychiatric population. EBioMedicine.2015; 2: 1405–1419.
4.
Yapici EserH, KacarAS, KilciksizCM, . Prevalence and associated features of anxiety disorder comorbidity in bipolar disorder: a meta-analysis and meta-regression study. Front Psychiatry.2018; 9: 229.
5.
PavlovaBPerlisRHAldaM. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry.2015; 2: 710–717.
6.
PretiAVrublevskaJVeronikiAA. Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis. Evid Based Ment Health.2016; 19: 73–81.
7.
SimonNMZaltaAKOttoMW. The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J Psychiatr Res.2007; 41: 255–264.
8.
AlbertURossoGMainaG. Impact of anxiety disorder comorbidity on quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. J Affect Disord.2008; 105: 297–303.
9.
Kauer-Sant'AnnaMFreyBNAndreazzaAC. Anxiety comorbidity and quality of life in bipolar disorder patients. Can J Psychiatry. 2007; 52: 175–181.
10.
ButurakSVKocakOM. Effects of comorbid anxiety disorders on the course of bipolar disorder-I. Nord J Psychiatry.2015; 69: 552–556.
11.
PerlisRHOstacherMJMiklowitzDJ. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry.2010; 71: 296–303.
12.
Lorenzo-LuacesLAmsterdamJDDeRubeisRJ. Residual anxiety may be associated with depressive relapse during continuation therapy of bipolar II depression. J Affect Disord.2018; 227: 379–383.
13.
ShahSKimJPParkDY. Lifetime anxiety disorder and current anxiety symptoms associated with hastened depressive recurrence in bipolar disorder. J Affect Disord.2017; 219: 165–171.
14.
GaudianoBAMillerIW. Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depress Anxiety.2005; 21: 71–77.
15.
KimSWBerkLKulkarniJ. Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder. J Affect Disord.2014; 166: 243–248.
16.
MclntyreRSSoczynskaJKBottasA. Anxiety disorders and bipolar disorder: a review. Bipolar Disord.2006; 8: 665–676.
17.
TohenMCalabreseJVietaE. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord.2007; 104: 137–146.
18.
BoylanKRBielingPJMarriottM. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry.2004; 65: 1106–1113.
19.
OttoMWSimonNMWisniewskiSR. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry.2006; 189: 20–25.
20.
CoryellWSolomonDAFiedorowiczJG. Anxiety and outcome in bipolar disorder. Am J Psychiatry.2009; 166: 1238–1243.
21.
ZimmermanMMartinJMcGonigalP. Validity of the DSM-5 anxious distress specifier for major depressive disorder. Depress Anxiety.2019; 36: 31–38.
22.
GasperszRLamersFKentJM. Longitudinal predictive validity of the DSM-5 anxious distress specifier for clinical outcomes in a large cohort of patients with major depressive disorder. J Clin Psychiatry.2017; 78: 207–213.
23.
GasperszRLamersFKentJM. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment. J Psychiatr Res.2017; 84: 41–48.
24.
MclntyreRSWeillerEZhangP. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials. J Affect Disord.2016; 201: 116–123.
25.
ShimIHWooYSBahkWM. Associations between immune activation and the current severity of the "with anxious distress" specifier in patients with depressive disorders. Gen Hosp Psychiatry.2016; 42: 27–31.
26.
MclntyreRSWoldeyohannesHOSoczynskaJK. The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Ther Adv Chronic Dis.2016; 7: 153–159.
27.
RoselliniAJBourgeoisMLCorreaJ. Anxious distress in depressed outpatients: prevalence, comorbidity, and incremental validity. J Psychiatr Res.2018; 103: 54–60.
28.
FirstMBSpitzerRLWilliamsJBW. Structured Clinical Interview for DSM-IV (SCID). Washington, DC: American Psychiatric Association; 1997.
29.
EndicottJSpitzerRL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry.1978; 35: 837–844.
CampbellDTFiskeDW. Convergent and discriminant validation by the multitrait multi-method matrix. Psychol Bull.1959; 56: 81–105.
38.
ZimmermanMMartinJClarkH. Measuring anxiety in depressed patients: a comparison of the Hamilton anxiety rating scale and the DSM-5 Anxious Distress Specifier Interview. J Psychiatr Res.2017; 93: 59–63.
39.
GenoveseTDalrympleKChelminskiI. Subjective anger and overt aggression in psychiatric outpatients. Compr Psychiatry.2017; 73: 23–30.
40.
SimonNMOttoMWWisniewskiSR. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry.2004; 161: 2222–2229.
41.
Kauer-SantAnnaMKapczinskiFVietaE.Epidemiology and management of anxiety in patients with bipolar disorder. CNS Drugs.2009; 23: 953–964.
42.
MerikangasKRAkiskalHSAngstJ. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry.2007; 64: 543–552.
